Reported research findings
- Evidence to date is preclinical and exploratory; no established human clinical trials define efficacy or safety in people.
HEALING & IMMUNE RESEARCH
KPV
A naturally occurring tripeptide (Lysine-Proline-Valine) studied for anti-inflammatory and tissue-protective effects.
KPV is the C-terminal tripeptide fragment of alpha-MSH, studied for potent anti-inflammatory, immunomodulatory, and tissue-protective effects without the pigmentation effects of full alpha-MSH. It is one of the most researched short peptides for inflammation and gut repair in preclinical and exploratory studies.
Why BLP features KPV
Included because it has a specific, well-defined anti-inflammatory mechanism (NF-κB and cytokine modulation) and a growing research following. Human clinical evidence remains preclinical and exploratory, so it is presented as experimental.
Mechanism
Strongly inhibits NF-κB activation, a master regulator of inflammation.
Reduces key pro-inflammatory cytokines (TNF-α, IL-1, IL-8) in epithelial and immune cells.
Supports epithelial barrier integrity and mucosal healing without broad immune suppression.
WHAT THE RESEARCH MEASURED
Research findings
Findings describe study outcomes, not expected personal results.
Preclinical findings
- In colitis/IBD models: significant reduction in inflammation and faster resolution.
- Reported accelerated mucosal and gut healing with restored barrier function.
- Reported calmer skin inflammation and enhanced wound repair.
- Naturally derived and very well tolerated in research use; rare mild injection-site reactions.
Regulatory status
KPV is investigational with primarily preclinical evidence. Sold and offered strictly for laboratory and research use.